FNDC5 and supranuclear palsy, progressive, 1: Sex‐specific treatment effects have been observed in hTau mice treated with the hormone irisin,147 in hTau.P301S (i.e., Tg2541) mice treated with colony‐stimulating factor‐1 receptor (CSF1R) inhibitors,148 and in clinical trials using davunetide for human PSP and mild cognitive impairment, where post hoc analyses revealed sex‐specific drug effects149, 150 that were not detected in pooled‐sex analyses.151, 152